<unk>  is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
Pralsetinib
Cobimetinib
Selumetinib
Binimetinib
Lestaurtinib
Larotrectinib
Luspatercept
Mobocertinib